Research Article

Effect of Exercise Intensity on Isoform-Specific Expressions of NT-PGC-1α mRNA in Mouse Skeletal Muscle

Xingyuan Wen,1 Jing Wu,1 Ji Suk Chang,2 Pengcheng Zhang,1 Jianzhu Wang,3 Yaliang Zhang,1 Thomas W. Gettys,3 and Yubin Zhang1

1 State Key Laboratory of Natural Medicines, Department of Biochemistry, China Pharmaceutical University, Nanjing 210009, China
2 Laboratory of Nutrient Sensing and Adipocyte Signaling, Pennington Biomedical Research Center, Baton Rouge, LA 70808, USA
3 Nanjing University of Chinese Medicine, Nanjing 210023, China

Correspondence should be addressed to Yubin Zhang; zhangyubin@gmail.com

Received 5 February 2014; Revised 2 April 2014; Accepted 28 April 2014; Published 2 July 2014

Academic Editor: Rajnish Chaturvedi

Copyright © 2014 Xingyuan Wen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PGC-1α is an inducible transcriptional coactivator that regulates mitochondrial biogenesis and cellular energy metabolism in skeletal muscle. Recent studies have identified two additional PGC-1α transcripts that are derived from an alternative exon 1 (exon 1b) and induced by exercise. Given that the PGC-1α gene also produces NT-PGC-1α transcript by alternative 3′ splicing between exon 6 and exon 7, we have investigated isoform-specific expression of NT-PGC-1α mRNA in mouse skeletal muscle during physical exercise with different intensities. We report here that NT-PGC-1α-a mRNA expression derived from a canonical exon 1 (exon 1a) is increased by high-intensity exercise and AMPK activator AICAR in mouse skeletal muscle but not altered by low- and medium-intensity exercise and β2-adrenergic receptor agonist clenbuterol. In contrast, the alternative exon 1b-driven NT-PGC-1α-b (PGC-1α4) and NT-PGC-1α-c are highly induced by low-, medium-, and high-intensity exercise, AICAR, and clenbuterol. Ectopic expression of NT-PGC-1α-a in C2C12 myotube cells upregulates myosin heavy chain (MHC I, MHC II a) and Glut4, which represent oxidative fibers, and promotes the expression of mitochondrial genes (Cyc1, COX5B, and ATP5B). In line with gene expression data, citrate synthase activity was significantly increased by NT-PGC-1α-a in C2C12 myotube cells. Our results indicate the regulatory role for NT-PGC-1α-a in mitochondrial biogenesis and adaptation of skeletal muscle to endurance exercise.

1. Introduction

PGC-1α is an inducible transcriptional coactivator that regulates cellular energy metabolism and metabolic adaptation to environmental and nutritional stimuli [1–3]. PGC-1α is induced in muscle by exercise and regulates energy metabolism and structural adaptation of muscle to exercise [4, 5]. PGC-1α stimulates many of the best-known beneficial effects of exercise in muscle: mitochondrial biogenesis, angiogenesis, and fiber-type switching [5, 6]. The health benefits of elevated expression of PGC-1α in muscle may go beyond the muscle tissue itself. The contracting muscle secretes myokines that participate in tissue crosstalk. PGC-1α promotes the production of newly identified hormone irisin from exercised muscle, increasing energy expenditure with no changes in movement or food intake [7]. Another contraction-induced myokine, beta-aminoisobutyric acid (BAIBA), induces browning of white adipose tissue and increases fat oxidation in the liver [8]. They could be therapeutics for human metabolic disease and other disorders that are improved with exercise.

Transcription of the PGC-1α gene can be driven by two different promoters in mouse and human skeletal muscle and adipose tissue [9, 10]. A proximal promoter is located upstream of a canonical exon 1 (exon 1a) and a distal promoter followed by an alternative exon 1 (exon 1b) is located ~13.7 kb upstream from the exon 1a of the PGC-1α gene (Figure I(a)) [9]. The PGC-1α-b and PGC-1α-c transcripts are derived by alternative splicing of the exon 1b at two different 5′ splice sites to the canonical exon 2, producing two PGC-1α isoforms, PGC-1α-b and PGC-1α-c, which actually have different N termini with the first 16 aa of PGC-1α-a being...
(a) Exon 1b 13.7 kb Exon 1a Exon 2

NT-PGC-1α-b (PGC-1α4)
PGC-1α-b
PGC-1α-c
PGC-1α-a
NT-PGC-1α-c
PGC-1α-a
PGC-1α-a

(b) ATGGCTTGGGACATGTGCAGCCAAGACTCTGTATGGAGTGACATAGAG
TGTCGCTGCT.............TCACCAA
AT TTGTTTTTATAAATGTGCCATATCTTCCAGTGACCCCAAGGGTTCCC

PGC-1α-b
PGC-1α-c
PGC-1α-a
NT-PGC-1α-c
NT-PGC-1α-b
NT-PGC-1α-a

(c) Corresponds to Primer pairs

Exon 1a: exon 7a
Exon 1a: exon 6/exon 7b
Exon 1b: exon 7a
Exon 1b: exon 6/exon 7b

Exon 1b': exon 7a
Exon 1b': exon 6/exon 7b
Exon 5: exon 7a
Exon 5: exon 6/exon 7b

(d) Figure 1: Continued.
Figure 1: Expression and identification of NT-PGC-1α-a, NT-PGC-1α-b, and NT-PGC-1α-c isoforms. (a) Schematic structure of the 5'-region of the murine PGC-1α gene. The schematic structure was slightly adapted from Miura et al. [9]. Boxes indicate promoters, exons, and lines introns. The coding regions and untranslated regions are shown in gray and white, respectively. The proximal promoter (P_prx) drives the transcription from exon 1a to produce NT-PGC-1α-a mRNA and PGC-1α-a mRNA. The alternative promoter (P_alt) drives the transcriptions from alternative exon 1b to generate NT-PGC-1α-b and PGC-1α-c mRNA and PGC-1α-b and PGC-1α-c mRNA. (b) Three different isoforms of NT-PGC-1α (NT-PGC-1α-a, NT-PGC-1α-b, and NT-PGC-1α-c) are produced by different exon usage and alternative 3' splicing at the intron between exons 6 and 7a which contains an in-frame stop codon TAA (red). Three different isoforms of PGC-1α (PGC-1α-a, PGC-1α-b, and PGC-1α-c) are produced by different exon usage and normal 3' splicing at the intron between exons 6 and 7b. (c) The schematic diagram of amino acid sequences of NT-PGC-1α-a, NT-PGC-1α-b, and NT-PGC-1α-c and PGC-1α-a, PGC-1α-b, and PGC-1α-c. The difference in amino acid sequences among NT-PGC-1α-a, NT-PGC-1α-b, and NT-PGC-1α-c is only in N-terminus shown in gray color, and the remaining sequences of NT-PGC-1α-a, NT-PGC-1α-b, and NT-PGC-1α-c are identical to each other. (d) Schematic diagrams of primer design for detection of NT-PGC-1α-a, NT-PGC-1α-b, and NT-PGC-1α-c mRNA and PGC-1α-a, PGC-1α-b, and PGC-1α-c mRNA. Primer pairs are depicted to the left, exons 1–7 of the PGC-1α gene are depicted to the middle, and the corresponding names of NT-PGC-1α and PGC-1α splice variants are stated to the right. Forward primers located in exon 1a (ex 1a) for NT-PGC-1α-a and PGC-1α-a, exon lb (ex lb) for NT-PGC-1α-b and PGC-1α-b, and exon lb'-exon 2 (ex lb'/ex 2) for NT-PGC-1α-c and PGC-1α-c were combined with reverse primers for NT-PGC-1α (ex 7a) and PGC-1α (ex 6/ex 7b). Reverse primers for total NT-PGC-1α (ex 7a) and total PGC-1α (ex 6/ex 7b) were combined with a common forward primer located in the junction of exons 5 and 6 (ex 5/ex 6). The detailed sequences of all primers above mentioned are listed in Table 1. (e) The slopes of the resulting standard curves relating log mass of NT-PGC-1α-a, NT-PGC-1α-b, NT-PGC-1α-c, PGC-1α-a, PGC-1α-b, and PGC-1α-c cDNA to cycle threshold are −3.968, −3.787, −3.748, −3.619, −3.837, and 3.868. (f) RT-PCR products of NT-PGC-1α-a, NT-PGC-1α-b, and NT-PGC-1α-c mRNA and PGC-1α-a, PGC-1α-b, and PGC-1α-c mRNA on agarose gel. The bands correspond to the calculated amplicon sizes: PGC-1α-a (770 bp), PGC-1α-b (800 bp), PGC-1α-c (768 bp), NT-PGC-1α-a (796 bp), NT-PGC-1α-b (831 bp), and NT-PGC-1α-c (799 bp). The normal PCR reaction conditions were 95°C for 10 min, 35 cycles of 95°C for 30 s, 60°C for 30 s, and 72°C for 1 min, and then 72°C for 5 min.

replaced by 12aa and 3aa alternate protein sequence in PGC-1α-b and PGC-1α-c, respectively (Figure 1(c)). PGC-1α-b and PGC-1α-c are functionally active and induce PPAR-dependent transcription to an extent comparable to PGC-1α-a. It was also shown that overexpression of PGC-1α-b or PGC-1α-c in skeletal muscle preferentially upregulated genes involved in mitochondrial biogenesis and fatty acid oxidation [9]. Low-, medium-, and high-intensity exercise and AICAR injection increased PGC-1α-b and PGC-1α-c transcripts via P2-AR activation, whereas high-intensity exercise or AICAR injection increased PGC-1α-a transcripts independently of P2-AR activation [11].

Our previous studies have shown that alternative splicing between exons 6 and 7 of the PGC-1α gene produces an additional transcript encoding the N-terminal isoform of PGC-1α (NT-PGC-1α), which consists of 267 amino acids of PGC-1α and 3 amino acids from the splicing insert [12]. NT-PGC-1α is a functional transcriptional coactivator since it retains the transcription activation and nuclear receptor interaction domains of PGC-1α [13–15]. In brown adipose tissue, three NT-PGC-1α mRNA isoforms (NT-PGC-1α-a, NT-PGC-1α-b, and NT-PGC-1α-c) derived from exon 1a or exon 1b are coexpressed with three PGC-1α isoforms and regulate thermogenic and mitochondrial gene expression in response to cold stress [16].

In this study, we investigated isoform-specific expression of NT-PGC-1α mRNA in mouse skeletal muscle in response to different intensities of exercise, AMPK activator AICAR, and β2-adrenergic receptor agonist clenbuterol. We reported here that NT-PGC-1α-a mRNA is induced only by high-intensity exercise and AICAR, whereas NT-PGC-1α-b and NT-PGC-1α-c mRNAs are induced by low-to-high-intensity exercise, AICAR, and clenbuterol. Moreover, ectopic expression of NT-PGC-1α-a activates the muscle transcription program in cultured myotube cells, enhancing mitochondrial oxidative capacity.

2. Materials and Methods

2.1. Experimental Animals. Six-week-old male C57BL/6J (18–22 g) mice were obtained from SLAC LABORATORY ANIMAL (Shanghai, China). Mice were acclimated for 1 week in a light-controlled room (12:12 h light-dark cycle) under a constant temperature (22°C); standard mouse chow and water were available ad libitum. All experiments were
approved by the Institutional Animal Care and Use Committee at China Pharmaceutical University and adhere to the Jiangsu Provincial Guidelines for the use of experimental animals.

2.2. Experimental Protocols. For running exercise experiments, mice were subjected to treadmill running at different intensity exercise, 10 m/min (low-intensity), 20 m/min (medium-intensity), and 30 m/min (high-intensity), for 30 min. Skeletal muscles (gastrocnemius) were isolated at 2 h after exercise [9, 17, 18]. For AICAR experiments, mice were injected with 250 mg/kg bw AICAR (i.p.) or the same volume of saline for 1 h, respectively [9, 11, 20]. C2C12 myotube cells in six-well plate were transiently transfected with 2.0 μg of NT-PGC-lα-a/pcDNA3.1 plasmids per well for 24 h using X-tremeGENE HP DNA transfection reagent (Roche, Germany). Then, cells were washed with phosphate-buffered saline and collected and frozen at –80°C until they were assayed.

2.4. RNA Isolation and Real-Time PCR (RT-PCR) Assay. Total RNA was extracted from mouse skeletal muscle (gastrocnemius) or C2C12 cells using TRIzol reagent (Invitrogen, USA). According to the manufacturer’s protocol, 50–100 mg of skeletal muscle was mixed with 1 mL of TRIzol and homogenized using Homogenizer (IKA-T-10, Germany). The cells in a well of 6-well plate were mixed with 1 mL of TRIzol. RNA was separated from protein and DNA by the addition of chloroform and precipitated in equal volume of cold isopropanol. After a 75% ethanol wash and resuspension in 20 μL of DEPC-treated ddH2O, RNA samples were quantified by spectrophotometry. 1 μg of total RNA was reverse-transcribed using Oligo(dT)18 primers and M-MLV reverse transcriptase (Roche, Germany) according to the protocol of First Strand cDNA Synthesis Kit (Roche, Germany) and 50 ng of cDNA was used as template for quantitative RT-PCR on Step One Plus System (Applied Biosystems, USA). The sequences of primers specific for PGC-lα-a, PGC-lα-b, and PGC-lα-c were designed (Figure 1(d)) and listed in Table 1. RT-PCR reactions were carried out in a 20 μL volume containing 1XFast Start Universal SYBR Green Master (ROX) (Roche, Germany), 50 ng cDNA, 0.3 μM forward and reverse primers (each).

Table I: Primer sequences for PCR analysis.

| Gene              | Forward primer                        | Reverse primer                        |
|-------------------|---------------------------------------|---------------------------------------|
| Total PGC-lα      | 5′-TGC CAT TGT TAA GAC CGA G-3′       | 5′-GAT CAT TTG GTG ACT CTG G-3′       |
| Total NT-PGC-lα   | 5′-TGC CAT TGT TAA GAC CGA G-3′       | 5′-GAT CAT TTG GTG ACT CTG G-3′       |
| NT-PGC-lα-a       | 5′-TTG ACT GGC GTC ATT CG-3′          | 5′-CTG GAA GAT ATG GCA CAT-3′        |
| NT-PGC-lα-b       | 5′-CAT GGA TTC ATT TTT GAA ATG-3′     | 5′-GAT CAT TGG AAG ATG C-3′          |
| NT-PGC-lα-c       | 5′-CTA TGC TGC TGT GTG CTG-3′        | 5′-GAT CAT TGG AAG ATG C-3′          |
| PGC-lα-a          | 5′-TTG ACT GGC GTC ATT CG-3′          | 5′-GAT CAT TGG ACT CTG G-3′          |
| PGC-lα-b          | 5′-CAT GGA TTC ATT TTT GAA ATG-3′     | 5′-GAT CAT TGG ACT CTG G-3′          |
| PGC-lα-c          | 5′-CTA TGC TGC TGT GTG CTG-3′        | 5′-GAT CAT TGG ACT CTG G-3′          |
| Glut4             | 5′-GAT GGT CTC GGT ACT AGT-3′        | 5′-GAT GAT AAG ATT CTC AGC G-3′      |
| ATP5B             | 5′-GGC ACT GAA GGC TTT GCT AG-3′     | 5′-GAT GAT AAG ATT CTC AGC G-3′      |
| Cyclin            | 5′-CCG TTT CAG TCA CAT C-3′          | 5′-GAT GAT AAG ATT CTC AGC G-3′      |
| COX5B             | 5′-GGC ACT GAA GGC TTT GCT AG-3′     | 5′-GAT GAT AAG ATT CTC AGC G-3′      |
| MHC I             | 5′-CCA ACG GCC TGA ATG AGG-3′        | 5′-GCA AAG GAT CCA GTG AG-3′        |
| MHC II a          | 5′-AAG CGA AGA GTA ATG CTG TC-3′     | 5′-GAT TGG TGC AAA GGA AC-3′        |
| MHC II b          | 5′-CAG CGA GGC AGG TAC GGT CA-3′     | 5′-GGT GAG CCA CTT GTA GGG GT-3′    |
| MHC II x          | 5′-GCC CGT GTG CTT GAT GGA AC-3′     | 5′-CTT CCG CTT CAG CTG TCT-3′      |
| IGF-1             | 5′-GTT GGT CGG ATA ATC CAG C-3′      | 5′-GAT GAT AAG ATT CTC AGC G-3′      |
| Myostatin         | 5′-GCC CAT GAT CCT GCT GTT AC-3′     | 5′-GAT GAT AAG ATT CTC AGC G-3′      |
| Cyclinophilin     | 5′-CCA TGG TGT CAT CAA GGA CTTC CAT-3′ | 5′-GAT GAT AAG ATT CTC AGC G-3′      |

PGC-lα: peroxisome proliferators-activated receptor-γ coactivator-lα; NT-PGC-lα: N-truncated PGC-lα; Glut4: glucose transporter 4; ATP5B: ATP synthase B subunit; Cyclin: cytochrome C unit I; COX5B: cytochrome oxidase 5B subunit; MHC I: myosin heavy chain I; MHC II a: myosin heavy chain II a; MHC II b: myosin heavy chain II b; MHC II x: myosin heavy chain II x; Cyclinophilin: peptidylprolyl isomerase B; IPG-1: insulin-like growth factor I.
qRT-PCR reaction conditions for long products (~800 bp) were 95°C for 10 min and then 40 cycles of 95°C for 15 s, 60°C for 30 s, and 72°C for 1 min [21, 22]. Target gene expression in each sample was normalized to the endogenous control gene cyclophilin. The relative expression among the different conditions (exercise or treatment groups) was determined using the ΔΔCt method as outlined in the Applied Biosystems protocol for RT-PCR.

2.5. Western Blot Analysis. C2C12 cells were homogenized and sonicated in ice-cold lysis buffer (RIPA) containing 50 mM Tris/HCl (pH 7.4), 150 mM NaCl, 1% SDS, 0.1% Triton X-100, 0.5% sodium deoxycholate, and protease inhibitor cocktail (Roche, Switzerland). Cell lysates were centrifuged at 12,000 × g for 5 min at 4°C. The concentration was determined with bicinchoninic acid (BCA) method. Equal amounts of total protein (100 μg) were loaded on 10% polyacrylamide gel (29:1 acrylamide-bisacrylamide), separated by SDS-PAGE, and transferred to PVDF membranes (Millipore, USA). The membrane was blocked for 1 h at room temperature in TBST buffer (50 mM Tris/HCl, 150 mM NaCl (pH 7.4), and 0.1% Tween-20) containing 5% nonfat dried milk. The membrane was incubated with the appropriate primary antibody in TBST with 5% nonfat dried milk overnight at 4°C. Primary antibody anti-PGC-1α mouse mAb (STI1202) (Calbiochem, USA) and anti-PGC-1α rabbit polyclonal antibody (SC-13067) (Santa Cruz, USA) were used to detect total PGC-1α due to the commercial antibody against the same N-terminal sequence of PGC-1α and PGC-1α but cannot distinguish each isoform of PGC-1α and NT-PCG-1α. The antibody can only detect total PGC-1α and NT-PCG-1α but cannot distinguish each isoform of PGC-1α and NT-PCG-1α. Immunoblots were hybridized with antibody raised against β-tubulin (Santa Cruz, USA) as loading control. The membrane was then washed 3 times with TBST and incubated for 1 h with HRP-conjugated secondary antibody. Finally, the immunoreactive proteins were visualized using chemiluminescence reagent (Amersham Biosciences, USA).

2.6. Citrate Synthase (CS) Assay. Citrate synthase activity was determined using a commercially available kit (Genmed, China). The principle of the assay is the reaction of acetyl-CoA with OAA (oxaloacetate) and the release of free CoA-SH, which reacts with a colorimetric reagent, DTNB [5,5-dithiobis(2-nitrobenzoate)], to form yellow colored compound (5-thio-2-nitrobenzoic acid (TNB)) [23]. The procedures were applied based on the manufacturer’s guideline. Briefly, C2C12 myotube cells transfected with NT-PCG-1α-a/pCDE3.1 were collected and lysed to disrupt the mitochondria and expose the CS. The supernatants were collected by centrifugation at 16,000 g for 5 min at 4°C. The protein concentration was measured by BCA method. 10 μL (20 μg) of total protein containing CS was added to test well containing reaction substrates reagent and 10 μL of negative control reagent was added to control well. The formation of 5-thio-2-nitrobenzoic acid was measured spectrophotometrically at 412 nm in 96-well format by using a microplate reader (Bio-Tek, USA) at 0 min and 15 min. All measurements were performed in duplicate in the same setting at 20–22°C. The CS activity was then normalized to the total protein content and was reported in as nanomoles per milligram protein per minute.

2.7. Statistical Analysis. Values are expressed as means ± S.E. Statistically significant differences were determined using unpaired Student’s t-tests. Statistical differences were considered significant if P < 0.05.

3. Results

3.1. Expression and Identification of NT-PCG-1α and PGC-1α Isoforms in Mouse Skeletal Muscle. Three PGC-1α isoforms, PGC-1α-a, PGC-1α-b, and PGC-1α-c, which are derived from either exon 1α or exon 1b, have been reported in skeletal muscle [9, 10]. In addition, the expressions of NT-PCG-1α-a, NT-PCG-1α-b, and NT-PCG-1α-c isoforms have been reported in brown adipose tissue [16]. They all arise from different promoter usage and alternative internal splicing (Figures 1(a), 1(b), and 1(c)). Thus, these previous studies suggest that the single PGC-1α gene can produce six different transcripts in skeletal muscle. To explore the isoform-specific expression of NT-PCG-1α mRNA in skeletal muscle, specific primers (Table 1) were designed to detect only NT-PCG-1α-a, NT-PCG-1α-b, and NT-PCG-1α-c mRNA as described in Figure 1(d). In addition, we designed a set of primers that detect only PGC-1α-a, PGC-1α-b, and PGC-1α-c mRNA (Figure 1(d)). The expression levels of NT-PCG-1α-a, NT-PCG-1α-b, and NT-PCG-1α-c and PGC-1α-a, PGC-1α-b, and PGC-1α-c can be quantitatively determined by qRT-PCR. The slopes of the resulting standard curves relating log mass of NT-PCG-1α-a, NT-PCG-1α-b, NT-PCG-1α-c, PGC-1α-a, PGC-1α-b, and PGC-1α-c cDNA to cycle threshold are -3.968, -3.787, -3.748, -3.619, -3.837, and 3.868 (Figure 1(e)). Each PCR product amplified by a specific set of primers was checked by agarose gel analysis (Figure 1(f)) and the specificity of PCR products was confirmed by DNA sequencing (data not shown).

3.2. Exercise Intensity-Dependent Expression of NT-PCG-1α mRNA Isoforms in Skeletal Muscle. To examine whether the expression of NT-PCG-1α mRNA isoforms is differentially induced in skeletal muscle in response to different intensities of exercise, C57BL/6J mice were subjected to treadmill running exercise at different intensities, 10 m/min (low-intensity), 20 m/min (medium-intensity), and 30 m/min (high-intensity), for 30 min according to the exercise program. Basal mRNA levels of NT-PCG-1α-b and NT-PCG-1α-c were very low when compared with that of NT-PCG-1α-a in control mice (Figure 2(a)). At low- and medium-intensity exercise, expression of NT-PCG-1α-a mRNA was not altered, but expression of NT-PCG-1α-b and NT-PCG-1α-c mRNA was significantly elevated (Figure 2(a)). After high-intensity exercise, NT-PCG-1α-b and NT-PCG-1α-c mRNA showed 97-fold and 28-fold increases in expression, respectively, whereas NT-PCG-1α-a mRNA levels increased by 2.1-fold (Figure 2(a)). It has been reported that a single exercise bout resulted in an increment in PGC-1 protein concentration [24]. In this study, we found that total NT-PCG-1α protein is a constitutive expression in skeletal muscle.
isoform-specific expression pattern in response to different intensities of exercise. (a) Induction of NT-PGC-1α-a, NT-PGC-1α-b, and NT-PGC-1α-c mRNA and total NT-PGC-1α mRNA in skeletal muscle (gastrocnemius) at low-, medium-, and high-intensity exercise in C57BL/6J mice. (b) Induction of total NT-PGC-1α protein expression in skeletal muscle (gastrocnemius) in C57BL/6J mice by exercise. C57BL/6J mice were subjected to treadmill running exercise at 20 m/min for 30 min. Gastrocnemius were separated 6 h, 12 h, and 18 h after exercise. Protein expression was analyzed by Western blotting, and β-tubulin was blotted as a loading control. (c) Induction of PGC-1α-a, PGC-1α-b, and PGC-1α-c mRNA and total PGC-1α mRNA in the same tissue and conditions above. Control mice were kept in cage without food. Gastrocnemius were separated 2 h after exercise. Relative gene expression was quantified by real-time PCR and relative to amount of each cDNA, compared to control mice. Values are means ± S.E. (n = 8). * P < 0.05 versus ctrl. Data are representative of three experiments.

3.3. AMPK Activator AICAR Increases the Expression of Three NT-PGC-1α mRNAs in Skeletal Muscle. AICAR is
a pharmacological activator of AMPK showing similar effects of exercise for increasing PGC-1α expression [11, 19], mitochondrial biogenesis, and fatty acid oxidation in skeletal muscle. To examine the effect of AMPK activation on isoform-specific expression of NT-PGC-1α mRNA in skeletal muscle, mice were injected i.p. with 250 mg/kg body weight AICAR or the same volume of saline. Skeletal muscles (gastrocnemius) were isolated after AICAR injection for 3 h, and gene expression was analyzed by qPCR. The expressions of NT-PGC-1α-a, NT-PGC-1α-b, and NT-PGC-1α-c mRNA were increased by 2.2-fold, 3.2-fold, and 2.4-fold, respectively (Figure 3(a)). In addition, a similar increase in PGC-1α-a, PGC-1α-b, and PGC-1α-c mRNA and total PGC-1α mRNA in the same tissue and conditions above. Control mice were injected by saline. Gastrocnemius were separated 3 h after injection. Relative gene expression was quantified by real-time PCR and relative to amount of each cDNA, compared to control mice. Values are means ± S.E. (n = 6). *P < 0.05 versus ctrl. Data are representative of three experiments.

3.4. β2-AR Agonist Clenbuterol Increases the Expression of NT-PGC-1α-b and NT-PGC-1α-c but Not NT-PGC-1α-a in Skeletal Muscle. Given that β2-adrenergic receptor agonist clenbuterol increases PGC-1α expression in skeletal muscle [4, 9, 11], we examined the effect of clenbuterol on isoform-specific expression of NT-PGC-1α mRNA. β2-AR agonist clenbuterol was subcutaneously injected to C57BL/6J mice at a dose of 1 mg/kg body weight in our experiments. The expressions of NT-PGC-1α-b and NT-PGC-1α-c mRNA were significantly increased by clenbuterol, whereas there was no change in mRNA levels of NT-PGC-1α-a (Figure 4(a)). Similarly, PGC-1α-b and PGC-1α-c mRNAs, but not PGC-1α-a mRNA, were largely induced by clenbuterol in skeletal muscle (Figure 4(b)), indicating that the alternative promoter of the PGC-1α gene is more responsive to β2-AR signaling.

3.5. NT-PGC-1α-a Enhances Mitochondrial Oxidative Function in C2C12 Myotube Cells. A recent study reported a muscle-specific PGC-1α isoform, PGC-1α4, which has shown to be induced by resistance training [17]. PGC-1α4 is actually identical to NT-PGC-1α-b, which is derived from exon lb of the PGC-1α gene. NT-PGC-1α-b (PGC-1α4) has shown to induce muscle cell hypertrophy but not mitochondrial biogenesis [17]. Given that NT-PGC-1α-a is induced by exercise in mouse skeletal muscle, we explored whether NT-PGC-1α-a regulates the transcription program in skeletal muscle. To test NT-PGC-1α-a function, differentiated C2C12 cells were used as a myotube cell model since no detectable NT-PGC-1α-a mRNA (data not shown) and protein (Figure 5(a)) were observed in differentiated C2C12 cells even after treatment with either AICAR or clenbuterol. Thus, overexpression of exogenous NT-PGC-1α-a was carried out by transfection of differentiated C2C12 cells with NT-PGC-1α-a (Figure 5(b)).

There are four muscle fiber types, Type I, Type II a, Type II b, and Type II x, which can be distinguished by the type of myosin heavy chain (MHC) isoform(s) [25, 26]. Type I fibers are referred to as being “slow twitch oxidative.” Type II a fibers
are “fast twitch oxidative.” Type II b fibers are “fast twitch glycolytic,” and Type II x fibers are intermediate to Type II a and II b fibers. Type I fibers have an oxidative profile with high mitochondrial content, capillary density, and glucose transporter 4 (Glut4) expression sensitive to insulin. We found that NT-PGC-1α-a promoted the expression of MHC I, MHC II a, and Glut4 in differentiated C2C12 cells by more than 30-fold, 20-fold, and 6-fold, respectively (Figure 6(a)), but decreased the expression of MHC II b and MHC II x by 60 percent and 70 percent (Figure 6(a)). These results indicate that NT-PGC-1α-a has a potential role in skeletal muscle adaptation to a more oxidative phenotype during endurance exercise.

IGF-1 plays an essential role in muscle development, muscle cell proliferation, and muscle growth [27]. Myostatin is a negative regulator of muscle growth and functions by inhibiting myoblast proliferation [28]. We found that NT-PGC-1α-a promoted the expression of IGF-1 in differentiated C2C12 cells by more than 1.5-fold (Figure 6(a)) but decreased the expression of myostatin by 70 percent (Figure 6(a)). These data demonstrated that NT-PGC-1α-a has a potential role in muscle development, muscle cell proliferation, and muscle growth.

To assess whether NT-PGC-1α-a expression alters mitochondrial biogenesis and function, several markers of mitochondrial biogenesis and function were examined in NT-PGC-1α-a-transfected C2C12 myotube cells. The mRNA expressions of mitochondrial component genes, Cyc1, COX5B, and ATP5B, were upregulated by 18.9-, 2-., and 1.5-fold, respectively, when compared with control C2C12

**Figure 4**: The effect of β2-AR activation on NT-PGC-1α-a, NT-PGC-1α-b, and NT-PGC-1α-c and PGC-1α-a, PGC-1α-b, and PGC-1α-c mRNA expression. (a) Expression of NT-PGC-1α-a, NT-PGC-1α-b, and NT-PGC-1α-c mRNA and total NT-PGC-1α mRNA in skeletal muscle (gastrocnemius) of C57BL/6J mice by the subcutaneous injection of β2-AR agonist clenbuterol at a dose of 1 mg/kg bw. (b) Expression of PGC-1α-a, PGC-1α-b, and PGC-1α-c mRNA and total PGC-1α mRNA in the same tissue and conditions above. Control mice were injected by saline. Gastrocnemius were separated 4 h after injection. Relative gene expression was quantified by real-time PCR and relative to amount of each cDNA, compared to control mice. Values are means ± S.E. (n = 6). *P < 0.05 versus ctrl. Data are representative of three experiments.

**Figure 5**: Ectopic expression of NT-PGC-1α-a protein in C2C12 myotubes. (a) No expression of endogenous NT-PGC-1α protein in differentiated C2C12 myotube cells induced by 10^{-5} M AICAR for 3 h and 10^{-5} M clenbuterol for 1 h. Control cells were treated with vehicle. (b) Expression of exogenous NT-PGC-1α-a protein in C2C12 myotube cells by transfection with plasmid NT-PGC-1α-a/pcDNA3.1. Control cells were transfected with pcDNA3.1 empty vector. Western blot analysis of NT-PGC-1α using an antibody raised against the N-terminal region of PGC-1α (aa 1–300). β-Tubulin was blotted as a loading control.
Figure 6: *In vitro* functional analysis of NT-PGC-1α-a. (a) NT-PGC-1α-a promotes oxidative phenotyping myotube fiber and the skeletal muscle mass growth. NT-PGC-1α-a induces the expression of MHC I, MHC IIα, Glut4, and IGF-1 mRNA and inhibits the expression of MHC IIβ, MHC IIx, and Myostatin mRNA in differentiated C2C12 cells transfected with plasmid NT-PGC-1α-a/pcDNA3.1. (b) NT-PGC-1α-a increases mitochondrial function through induction of ATP5B, COX5B, and Cyc1 mRNA expression in the same cells and conditions above. Relative gene expression was quantified by real-time PCR and normalized to the expression of cyclophilin with C_T method, compared to control cells transfected with empty vector pcDNA3.1. Values are means ± S.E. (n = 3). *P < 0.05 versus ctrl. (c) NT-PGC-1α-a enhances the activity of citrate synthase in C2C12 myotube cells transfected with plasmid NT-PGC-1α-a/pcDNA3.1. The activity is normalized to the total protein content of the sample used in the assay. Normalized data are presented as means ± S.E. *P < 0.05 versus ctrl. (∗P < 0.05, significantly different from control).

cells transfected by an empty vector pcDNA3.1 (P < 0.05; Figure 6(b)). These nuclear DNA-encoded mitochondrial proteins are critical for mitochondrial biogenesis and oxidative metabolism. Citrate synthase is one of the key regulatory enzymes in an energy-generating metabolic pathway [23]. It has been extensively used as a metabolic marker for assessing mitochondrial oxidative capacity. The activity of citrate synthase in NT-PGC-1α-transfected C2C12 myotube cells was 1.4-fold higher than that of control C2C12 cells (Figure 6(c)). This is consistent with the studies reporting the acute increase in CS activity in skeletal muscle after a single bout of exercise [23].

4. Discussion

The PGC-1α gene has been thought to produce single transcript and protein. However, recent studies reported that multiple mRNAs are produced from the PGC-1α gene by different exon usage and alternative splicing in skeletal muscle and brown adipose tissue [9, 10]. We show here
that NT-PGC-\(\alpha\)-a, NT-PGC-\(\alpha\)-b, and NT-PGC-\(\alpha\)-c are coexpressed with PGC-\(\alpha\)-a, PGC-\(\alpha\)-b, and PGC-\(\alpha\)-c in mouse skeletal muscle. Consistent with the previous findings on PGC-\(\alpha\) expression in mouse skeletal muscle, isoform-specific expression of NT-PGC-\(\alpha\) mRNA was dependent on exercise intensity [11]. Exon 1a-driven NT-PGC-\(\alpha\)-a was induced by both high-intensity exercise and AMPK activation but not by \(\beta_2\)AR stimulation, whereas expression of exon 1b-driven NT-PGC-\(\alpha\)-b and NT-PGC-\(\alpha\)-c were markedly elevated by low-to-high-intensity exercise, AICAR, and clenbuterol. Transcriptional shift between exon 1a and exon 1b of the PGC-\(\alpha\) gene may imply isoform-specific roles for NT-PGC-\(\alpha\) in basal and exercised conditions. The further studies on the underlying mechanism involving transcription factors on the proximal and alternative promoters and the physiological regulation of proximal and alternative promoters are warranted. In addition, it is also important to explore the molecular mechanism and regulation of the alternative splicing that produce NT-PGC-\(\alpha\) from posttranscription modification of PGC-\(\alpha\) pre-mRNA in different physiological and pathological conditions.

The exercise-inducible and exon 1b-driven NT-PGC-\(\alpha\)-b is actually identical to a recently identified muscle-specific PGC-\(\alpha\) isoform, PGC-\(\alpha\)-4 [17]. PGC-\(\alpha\)-4 has shown to be induced by resistance training, but not by endurance training, and regulate skeletal muscle mass [17]. However, we observed here that NT-PGC-\(\alpha\)-b expression is largely elevated by low-to-high endurance exercise, AMPK activation, and \(\beta_2\)-AR activation in mouse skeletal muscle. In agreement with our findings, a recent study has reported that NT-PGC-\(\alpha\)-b (PGC-\(\alpha\)-4) is induced by both endurance and resistance exercise in human skeletal muscle [18]. Moreover, PGC-\(\alpha\)-b expression was largely elevated by endurance exercise, AMPK activation, and \(\beta_2\)-AR activation in mouse skeletal muscle. Skeletal muscle-specific expression of PGC-\(\alpha\)-b has shown to increase mitochondrial biogenesis and exercise capacity [9, 29].

Type I fibers containing MHC I are referred to as being “slow twitch oxidative” and have an oxidative profile with high mitochondrial content, capillary density, and glucose transporter 4 (Glut4) expression sensitive to insulin. Type IIa fibers expressing MHC IIa are fatigue resistant and have the highest oxidative (aerobic) capacity of the fast fibers with numerous mitochondria. Type IIb fibers are the fastest contracting and fatigue-resistant fibers which contain Type MHC IIb and few mitochondria, using primarily glycolytic (anaerobic) pathways to generate energy for contraction [25, 26]. Type I fibers are characterized by low force/power/speed production and high endurance, Type IIb and Type II x fibers are characterized by high force/power/speed production and low endurance, while Type IIa fibers fall in between [26]. Here, we clearly showed that overexpression of NT-PGC-\(\alpha\)-a in cultured C.\(\alpha\)C.\(\alpha\) myotubes upregulates the expression of myosin heavy chain I and II a (MHC I, MHC IIa), glucose transporter 4 (Glut4), and insulin-like growth factor 1 (IGF-1), while reducing MHC IIb, MHC II x, and myostatin mRNA expression. Furthermore, NT-PGC-\(\alpha\)-a induced the expression of mitochondrial respiratory subunit (COX5B, Cyc1, and ATP5B) and increased the mitochondrial oxidative enzyme CS activities. However, NT-PGC-\(\alpha\)-b (PGC-\(\alpha\)-4) and PGC-\(\beta\) have shown to induce the expression of MHC II x, but not MHC I, in skeletal muscle [17, 30]. Furthermore, NT-PGC-\(\alpha\)-b (PGC-\(\alpha\)-4) has shown to promote muscle development, muscle cell proliferation, and muscle growth [17]. These data suggested that NT-PGC-\(\alpha\)-a promotes muscle fiber switching to more oxidative phenotype in gastrocnemius with increased mitochondrial biogenesis and muscle growth. The presence and differential expression of multiple PGC-\(\alpha\) and NT PGC-\(\alpha\) isoforms may enhance the ability of skeletal muscle to optimally adapt to different intensities of exercise.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Authors’ Contribution

Xingyuan Wen and Jing Wu contributed equally to this work.

Acknowledgments

This work was supported by the National Natural Science Foundation of China Grant 81072679 to Yubin Zhang; Opening Project of Shanghai Key Laboratory of Complex Prescription, Shanghai University of T.C.M. (1IDZ2272300); and a project funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD); and COBRE Grant NIH P20-GM103528 to Ji Suk Chang and Thomas W. Gettys.

References

[1] P. Puigserver, Z. Wu, C. W. Park, R. Graves, M. Wright, and B. M. Spiegelman, “A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis,” Cell, vol. 92, no. 6, pp. 829–839, 1998.
[2] J.-D. Lin, C. Handschin, and B. M. Spiegelman, “Metabolic control through the PGC-1 family of transcription coactivators,” Cell Metabolism, vol. 1, no. 6, pp. 361–370, 2005.
[3] C. Kang and L. L. Ji, “Role of PGC-\(\alpha\) signaling in skeletal muscle health and disease,” Annals of the New York Academy of Sciences, vol. 1271, no. 1, pp. 110–117, 2012.
[4] S. Miura, K. Kawanaka, Y. Kai et al., “An increase in murine skeletal muscle peroxisome proliferator-activated receptor-\(\gamma\) coactivator-\(\alpha\) (PGC-\(\alpha\)) mRNA in response to exercise is mediated by \(\beta\)-adrenergic receptor activation,” Endocrinology, vol. 148, no. 7, pp. 3441–3448, 2007.
[5] C. Handschin and B. M. Spiegelman, “The role of exercise and PGC\(\alpha\) in inflammation and chronic disease,” Nature, vol. 454, no. 7203, pp. 463–469, 2008.
[6] J. Lin, H. Wu, P. T. Tarr et al., “Transcriptional co-activator PGC-\(\alpha\) drives the formation of slow-twitch muscle fibres,” Nature, vol. 418, no. 6899, pp. 797–801, 2002.
[7] P. Bostrom, J. Wu, M. P. Jedrychowski et al., “A PGC1\(\alpha\)-dependent myokine that drives brown-fat-like development of white fat and thermogenesis,” Nature, vol. 481, no. 7382, pp. 463–468, 2012.
[8] L. D. Roberts, P. Boström, J. F. O’Sullivan et al., “β-Aminoisobutyric acid induces browning of white fat and hepatic β-oxidation and is inversely correlated with cardiometabolic risk factors,” Cell Metabolism, vol. 19, no. 1, pp. 96–108, 2014.

[9] S. Miura, Y. Kai, Y. Kamei, and O. Ezaki, “Isomform-specific increases in murine skeletal muscle peroxisome proliferator-activated receptor-γ coactivator-ⅰα (PGC-1α) mRNA in response to β2-adrenergic receptor activation and exercise,” Endocrinology, vol. 149, no. 9, pp. 4527–4533, 2008.

[10] T. Yoshioka, K. Inagaki, T. Noguchi et al., “Identification and characterization of an alternative promoter of the human PGC-ⅰα gene,” Biochemical and Biophysical Research Communications, vol. 381, no. 4, pp. 537–543, 2009.

[11] M. Tadaishi, S. Miura, Y. Kai et al., “Effect of exercise intensity and AICAR on isomform-specific expressions of murine skeletal muscle PGC-ⅰα mRNA: a role of β2-adrenergic receptor activation,” American Journal of Physiology: Endocrinology and Metabolism, vol. 300, no. 2, pp. E341–E349, 2011.

[12] Y. Zhang, P. Huypens, A. Adamson et al., “Alternative mRNA splicing produces a novel biologically active short isoform of PGC-ⅰα,” The Journal of Biological Chemistry, vol. 284, no. 47, pp. 32813–32826, 2009.

[13] J. S. Chang, P. Huypens, Y. Zhang, C. Black, A. Kralli, and T. W. Gettys, “Regulation of NT-PGC-ⅰα subcellular localization and function by protein kinase A-dependent modulation of nuclear export by CRM1,” Journal of Biological Chemistry, vol. 285, no. 23, pp. 18039–18050, 2010.

[14] H. Jun, T. W. Gettys, and J. S. Chang, “Transcriptional activity of PGC-ⅰα and NT-PGC-ⅰα is differentially regulated by twist-1 in brown fat metabolism,” PPAR Research, vol. 2012, Article ID 320454, 7 pages, 2012.

[15] A. Johri, A. A. Starkov, A. Chandra et al., “Truncated peroxisome proliferator-activated receptor-γ coactivator ⅰα splice variant is severely altered in Huntington’s disease,” Neurodegenerative Diseases, vol. 8, no. 6, pp. 496–503, 2011.

[16] J. S. Chang, V. Fernand, Y. Zhang et al., “NT-PGC-ⅰα protein is sufficient to link β2-adrenergic receptor activation to transcriptional and physiological components of adaptive thermogenesis,” Journal of Biological Chemistry, vol. 287, no. 12, pp. 9100–9111, 2012.

[17] J. L. Ruas, J. P. White, R. R. Rao et al., “A PGC-ⅰα isoform induced by resistance training regulates skeletal muscle hypertrophy,” Cell, vol. 151, no. 6, pp. 1319–1331, 2012.

[18] M. Ydfors, H. Fischer, and H. Mascher, “The truncated splice variants, NT-PGC-ⅰα and PGC-ⅰα4, increase with both endurance and resistance exercise in human skeletal muscle,” Physiological Reports, vol. 1, no. 6, Article ID e00140, 2013.

[19] S. Jäger, C. Handschin, J. S. Pierre, and B. M. Spiegelman, “AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-ⅰα,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 29, pp. 12017–12022, 2007.

[20] V. A. Lira, D. L. Brown, A. K. Lira et al., “Nitric oxide and AMPK cooperatively regulate PGC-ⅰα in skeletal muscle cells,” Journal of Physiology, vol. 588, no. 18, pp. 3551–3566, 2010.

[21] C. Stormo, M. K. Kringen, R. M. Grimholt, J. P. Berg, and A. P. Pichler, “A novel 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) splice variant with an alternative exon 1 potentially encoding an extended N-terminus,” BMC Molecular Biology, vol. 13, article 29, 2012.